Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Admilparant - Bristol-Myers Squibb

Next Previous
Drug Profile

Admilparant - Bristol-Myers Squibb

Alternative Names: BMS-986278

Latest Information Update: 20 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antifibrotics; Carbamates; Cyclohexanecarboxylic acids; Hepatoprotectants; Pyridines; Small molecules; Triazoles
  • Mechanism of Action LPAR1 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Idiopathic pulmonary fibrosis; Pulmonary fibrosis

Most Recent Events

  • 12 Oct 2026 Efficacy and adverse events data from the phase III ALOFT-IPF trial in Idiopathic pulmonary fibrosis released by Bristol-Myers Squibb
  • 14 Jun 2026 Bristol-Myers Squibb completes a phase I trial in Healthy volunteers in USA (PO) (NCT07422298)
  • 20 May 2026 Bristol-Myers Squibb completes enrolment in the ALOFT-IPF trial for Idiopathic pulmonary fibrosis in Austria, Belgium, Brazil, Canada, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, Netherlands, Peru, Poland, Portugal, Puerto Rico, Spain, Switzerland, Turkey, United Kingdom, USA, Argentina, Australia, Chile, China, Japan, Israel, South Korea, Taiwan and Mexico (NCT06003426)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top